Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000034174 | SCV001202580 | pathogenic | Hereditary spastic paraplegia 11 | 2023-12-12 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Leu491Aspfs*66) in the SPG11 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in SPG11 are known to be pathogenic (PMID: 19105190, 20110243, 22154821, 26556829). This variant is present in population databases (rs312262727, gnomAD 0.008%). This premature translational stop signal has been observed in individual(s) with hereditary spastic paraplegia (PMID: 18079167, 27217339). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 41273). For these reasons, this variant has been classified as Pathogenic. |
Paris Brain Institute, |
RCV000034174 | SCV001451245 | pathogenic | Hereditary spastic paraplegia 11 | criteria provided, single submitter | clinical testing | ||
Genome- |
RCV000034174 | SCV002764132 | pathogenic | Hereditary spastic paraplegia 11 | criteria provided, single submitter | clinical testing | ||
Fulgent Genetics, |
RCV005007928 | SCV005637749 | pathogenic | Amyotrophic lateral sclerosis type 5; Hereditary spastic paraplegia 11; Charcot-Marie-Tooth disease axonal type 2X | 2024-02-27 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000034174 | SCV000058112 | not provided | Hereditary spastic paraplegia 11 | no assertion provided | literature only |